Cardiac congenital diseases are rare inherited disorders characterized by anatomical malformations and/or by electrophysiological abnormalities, both affecting the whole heart function. In order to clarify the underlying pathophysiological mechanisms, experimental modeling has been proposed through in silico, in vitro, and/or in vivo simulations. Bioinformatics, transgenesis, heterologous expression systems, mammalian models, and, recently, pluripotent stem cells have been advanced to effectively recapitulate several human congenital diseases (such as Brugada syndrome, CPVT, LQTs, and ARVC) and, potentially, provide new insights into their pathomechanisms for novel therapeutic perspectives. 1. Introduction Cardiac congenital diseases are malformations of the heart, with lethal consequences in the fetal life or able to compromise the cardiovascular function often soon after birth. From simpler forms, as the atrial septal defects, to more complex abnormalities, as the complete atrioventricular canal and the Tetralogy of Fallot, such class of structural heart diseases has incidence per 1000 live births varying from an average 6.9 in Europe to 9.3 in Asia or 8 in the United States. The more severe symptoms can manifest in the first year of life: frequently, they are recognized only after infant death or when promptly diagnosed, require urgent surgical correction in approximately 25% cases. They might also be asymptomatic until the adult age in the so-called GUCH population (grown-up congenital heart) [1]. In other cases, congenital cardiac diseases are not related to morpho-anatomical defects of the heart but caused by mutations in important proteins related to its global function. In macroscopically normal hearts, ion channels, transporters, and other accessory proteins can be interested by molecular anomalies affecting their cardinal properties, thus resulting in a deregulation of the normal electromechanical coupling. Encoded by almost 350 genes, the large family of ion channels comprises proteins with a unique domain or multiple subunits, arranged in different topologies at the cell membrane. Owing to precise selective and gating features, they allow the passive flow of specific ions through their pores across the membrane interface and differ from ion pumps or sym/antiporters since they do not require energy to regulate the electrochemical movement. Many accessory proteins tune the biophysical activities of these molecular switches either as their subdomains or as specialized chaperone or anchoring units [2]. In the cardiomyocyte electromechanical
References
[1]
“Heart disease & stroke statistics—2013 update from the American Heart Association”.
[2]
F. M. Ashcroft, “From molecule to malady,” Nature, vol. 440, no. 7083, pp. 440–447, 2006.
[3]
M. Cerrone and S. G. Priori, “Genetics of sudden death: focus on inherited channelopathies,” European Heart Journal, vol. 32, no. 17, pp. 2109–2120, 2011.
[4]
A. L. Hodgkin and A. F. Huxley, “A quantitative description of membrane current and its application to conduction and excitation in nerve,” The Journal of Physiology, vol. 117, no. 4, pp. 500–544, 1952.
[5]
R. J. French and R. Horn, “Sodium channel gating: models, mimics, and modifiers,” Annual Review of Biophysics and Bioengineering, vol. 12, pp. 319–356, 1983.
[6]
F. H. Fenton and E. M. Cherry, “Models of cardiac cell,” Scholarpedia, vol. 3, no. 8, article 1868, 2008.
[7]
D. Noble and Y. Rudy, “Models of cardiac ventricular action potentials: iterative interaction between experiment and simulation,” Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol. 359, no. 1783, pp. 1127–1142, 2001.
[8]
R. E. McAllister, D. Noble, and R. W. Tsien, “Reconstruction of the electrical activity of cardiac Purkinje fibres,” Journal of Physiology, vol. 251, no. 1, pp. 1–59, 1975.
[9]
G. W. Beeler and H. Reuter, “Reconstruction of the action potential of ventricular myocardial fibres,” Journal of Physiology, vol. 268, no. 1, pp. 177–210, 1977.
[10]
D. DiFrancesco and C. Ojeda, “Properties of the current if in the sino-atrial node of the rabbit compared with those of the current iK, in Purkinje fibres,” Journal of Physiology, vol. 308, pp. 353–367, 1980.
[11]
D. DiFrancesco and D. Noble, “A model of cardiac electrical activity incorporating ionic pumps and concentration changes,” Philosophical transactions of the Royal Society of London. Series B: Biological sciences, vol. 307, no. 1133, pp. 353–398, 1985.
[12]
C.-H. Luo and Y. Rudy, “A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction,” Circulation Research, vol. 68, no. 6, pp. 1501–1526, 1991.
[13]
C.-H. Luo and Y. Rudy, “A dynamic model of the cardiac ventricular action potential: I. Simulations of ionic currents and concentration changes,” Circulation Research, vol. 74, no. 6, pp. 1071–1096, 1994.
[14]
K. H. W. J. Ten Tusscher, D. Noble, P. J. Noble, and A. V. Panfilov, “A model for human ventricular tissue,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 286, no. 4, pp. H1573–H1589, 2004.
[15]
A. F. Huxley, “Muscle structure and theories of contraction,” Progress in Biophysics and Biophysical Chemistry, vol. 7, pp. 255–318, 1957.
[16]
V. S. Markhasin, O. Solovyova, L. B. Katsnelson, Y. Protsenko, P. Kohl, and D. Noble, “Mechano-electric interactions in heterogeneous myocardium: development of fundamental experimental and theoretical models,” Progress in Biophysics and Molecular Biology, vol. 82, no. 1–3, pp. 207–220, 2003.
[17]
J. J. Rice, F. Wang, D. M. Bers, and P. P. de Tombe, “Approximate model of cooperative activation and crossbridge cycling in cardiac muscle using ordinary differential equations,” Biophysical Journal, vol. 95, no. 5, pp. 2368–2390, 2008.
[18]
S. A. Niederer, G. Plank, P. Chinchapatnam et al., “Length-dependent tension in the failing heart and the efficacy of cardiac resynchronization therapy,” Cardiovascular Research, vol. 89, no. 2, pp. 336–343, 2011.
[19]
S. Kupershmidt, I. C.-H. Yang, M. Sutherland et al., “Cardiac-enriched LIM domain protein fhl2 is required to generate in a heterologous system,” Cardiovascular Research, vol. 56, no. 1, pp. 93–103, 2002.
[20]
S.-H. Jo, J. B. Youm, I. Kim, C. O. Lee, Y. E. Earm, and W.-K. Ho, “Blockade of HERG channels expressed in Xenopus oocytes by external H+,” Pflügers Archiv, vol. 438, no. 1, pp. 23–29, 1999.
[21]
P. Tammaro, K. Shimomura, and P. Proks, “Xenopus oocytes as a heterologous expression system for studying ion channels with the patch-clamp technique,” Methods in Molecular Biology, vol. 491, pp. 127–139, 2008.
[22]
W. J. Crumb and I. Cavero, “Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds,” Current Protocols in Pharmacology, vol. 10, unit 10.8, 2003.
[23]
W. Crumb and I. Cavero, “QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development,” Pharmaceutical Science and Technology Today, vol. 2, no. 7, pp. 270–280, 1999.
[24]
B. Jiang, G. Tang, K. Cao, L. Wu, and R. Wang, “Molecular mechanism for H2S-induced activation of channels,” Antioxidants and Redox Signaling, vol. 12, no. 10, pp. 1167–1178, 2010.
[25]
J. S. Mitcheson, J. C. Hancox, and A. J. Levi, “Action potentials, ion channel currents and transverse tubule density in adult rabbit ventricular myocytes maintained for 6 days in cell culture,” Pflügers Archiv, vol. 431, no. 6, pp. 814–827, 1996.
[26]
S. L. Jacobson, “Culture of spontaneously contracting myocardial cells from adult rats,” Cell Structure and Function, vol. 2, no. 1, pp. 1–9, 1977.
[27]
L. B. Bugaisky and R. Zak, “Differentiation of adult rat cardiac myocytes in cell culture,” Circulation Research, vol. 64, no. 3, pp. 493–500, 1989.
[28]
P. R. Fox, B. J. Maron, C. Basso, S.-K. Liu, and G. Thiene, “Spontaneously occurring arrhythmogenic right ventricular cardiomyopathy in the domestic cat: a new animal model similar to the human disease,” Circulation, vol. 102, no. 15, pp. 1863–1870, 2000.
[29]
C. Basso, P. R. Fox, K. M. Meurs et al., “Arrhythmogenic right ventricular cardiomyopathy causing sudden cardiac death in boxer dogs: a new animal model of human disease,” Circulation, vol. 109, no. 9, pp. 1180–1185, 2004.
[30]
K. E. Odening, M. Kirk, M. Brunner et al., “Electrophysiological studies of transgenic long QT type 1 and type 2 rabbits reveal genotype-specific differences in ventricular refractoriness and His conduction,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 299, no. 3, pp. H643–H655, 2010.
[31]
F. Charpentier, A. Bourgé, and J. Mérot, “Mouse models of SCN5A-related cardiac arrhythmias,” Progress in Biophysics and Molecular Biology, vol. 98, no. 2-3, pp. 230–237, 2008.
[32]
B. London, L. C. Baker, P. Petkova-Kirova, J. M. Nerbonne, B.-R. Choi, and G. Salama, “Dispersion of repolarization and refractoriness are determinants of arrhythmia phenotype in transgenic mice with long QT,” Journal of Physiology, vol. 578, no. 1, pp. 115–129, 2007.
[33]
D. E. Gutstein, G. E. Morley, H. Tamaddon et al., “Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43,” Circulation Research, vol. 88, no. 3, pp. 333–339, 2001.
[34]
E. M. Lodder and S. Rizzo, “Mouse models in arrhythmogenic right ventricular cardiomyopathy,” Frontiers in Electrophysiology, vol. 3, article 221, 2012.
[35]
T. O'Hara and Y. Rudy, “Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 302, no. 5, pp. H1023–H1030, 2012.
[36]
I. M. Ayoub, J. Kolarova, Z. Yi et al., “Sodium-hydrogen exchange inhibition during ventricular fibrillation: beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitability,” Circulation, vol. 107, no. 13, pp. 1804–1809, 2003.
[37]
G.-R. Li, X.-L. Du, Y. L. Siow, O. Karmin, H.-F. Tse, and C.-P. Lau, “Calcium-activated transient outward chloride current and phase 1 repolarization of swine ventricular action potential,” Cardiovascular Research, vol. 58, no. 1, pp. 89–98, 2003.
[38]
J. M. Nerbonne, “Studying cardiac arrhythmias in the mouse—a reasonable model for probing mechanisms?” Trends in Cardiovascular Medicine, vol. 14, no. 3, pp. 83–93, 2004.
[39]
A. M. From, J. J. Maleszewski, and C. S. Rihal, “Current status of endomyocardial biopsy,” Mayo Clinic Proceedings, vol. 86, no. 11, pp. 1095–1102, 2011.
[40]
R. K. Li, L. C. Tumiati, R. D. Weisel, and D. A. G. Mickle, “Isolation of cardiomyocytes from human myocardium for primary cell culturing,” Journal of Tissue Culture Methods, vol. 15, no. 3, pp. 147–154, 1993.
[41]
J. A. Thomson, “Embryonic stem cell lines derived from human blastocysts,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998.
[42]
K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
[43]
K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[44]
T. Seki, S. Yuasa, and K. Fukuda, “Derivation of induced pluripotent stem cells from human peripheral circulating T cells,” Current Protocols in Stem Cell Biology, vol. 18, pp. 4A.3.1–4A.3.9, 2011.
[45]
W. Yang, J. A. Mills, S. Sullivan, Y. Liu, D. L. French, and P. Gadue, “iPSC reprogramming from human peripheral blood using sendai virus mediated gene transfer,” in StemBook, Harvard Stem Cell Institute, Cambridge, Mass, USA, 2008–2012.
[46]
C. Mauritz, K. Schwanke, M. Reppel et al., “Generation of functional murine cardiac myocytes from induced pluripotent stem cells,” Circulation, vol. 118, no. 5, pp. 507–517, 2008.
[47]
A. Moretti, M. Bellin, C. B. Jung et al., “Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors,” FASEB Journal, vol. 24, no. 3, pp. 700–711, 2010.
[48]
C. Terrenoire, K. Wang, K. W. Tung et al., “Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics,” The Journal of General Physiology, vol. 141, no. 1, pp. 61–72, 2013.
[49]
A. Margariti, B. Winkler, E. Karamariti et al., “Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, pp. 13793–13798, 2012.
[50]
W.-H. Zimmermann and T. Eschenhagen, “Embryonic stem cells for cardiac muscle engineering,” Trends in Cardiovascular Medicine, vol. 17, no. 4, pp. 134–140, 2007.
[51]
S. L. J. Ng, K. Narayanan, S. Gao, and A. C. A. Wan, “Lineage restricted progenitors for the repopulation of decellularized heart,” Biomaterials, vol. 32, no. 30, pp. 7571–7580, 2011.
[52]
C. Rao, H. Barratt, T. Prodromakis, and C. M. Terracciano, “Tissue engineering techniques in cardiac repair and disease modelling,” Current Pharmaceutical Design, 2013.
[53]
C. L. Mummery, J. Zhang, E. S. Ng, D. A. Elliott, A. G. Elefanty, and T. J. Kamp, “Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview,” Circulation Research, vol. 111, no. 3, pp. 344–358, 2012.
[54]
A. L. George Jr., “Molecular and genetic basis of sudden cardiac death,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 75–83, 2013.
[55]
L. Xia, Y. Zhang, and X. H. Lu, “Cellular modeling and simulation of brugada syndrome,” in Proceedings of the Computers in Cardiology (CinC '05), pp. 1001–1004, Lyon, France, September 2005.
[56]
G.-X. Yan and C. Antzelevitch, “Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation,” Circulation, vol. 100, no. 15, pp. 1660–1666, 1999.
[57]
J. M. Fish and C. Antzelevitch, “Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes,” Journal of Electrocardiology, vol. 36, supplement 1, pp. 173–179, 2003.
[58]
K. Nishida, A. Fujiki, K. Mizumaki et al., “Canine model of Brugada syndrome using regional epicardial cooling of the right ventricular outflow tract,” Journal of Cardiovascular Electrophysiology, vol. 15, no. 8, pp. 936–941, 2004.
[59]
P. G. Meregalli, A. A. M. Wilde, and H. L. Tan, “Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?” Cardiovascular Research, vol. 67, no. 3, pp. 367–378, 2005.
[60]
G. A. Papadatos, P. M. R. Wallerstein, C. E. G. Head et al., “Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6210–6215, 2002.
[61]
R. P. Davis, S. Casini, C. W. van den Berg et al., “Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease,” Circulation, vol. 125, no. 25, pp. 3079–3091, 2012.
[62]
M. Cerrone, C. Napolitano, and S. G. Priori, “Catecholaminergic polymorphic ventricular tachycardia: a paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation,” Heart Rhythm, vol. 6, no. 11, pp. 1652–1659, 2009.
[63]
F. J. Amador, P. B. Stathopulos, M. Enomoto, and M. Ikura, “Ryanodine receptor calcium release channels: lessons from structure-function studies,” FEBS Journal, vol. 280, no. 21, pp. 5456–5470, 2013.
[64]
T. Guo, R. L. Cornea, S. Huke et al., “Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks,” Circulation Research, vol. 106, no. 11, pp. 1743–1752, 2010.
[65]
D. Jiang, R. Wang, B. Xiao et al., “Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death,” Circulation Research, vol. 97, no. 11, pp. 1173–1181, 2005.
[66]
D. Jiang, P. P. Jones, D. R. Davis et al., “Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia,” Channels, vol. 4, no. 4, pp. 302–310, 2010.
[67]
S. G. Priori, C. Napolitano, N. Tiso et al., “Mutataions in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia,” Circulation, vol. 103, no. 2, pp. 196–200, 2001.
[68]
N. Liu, B. Colombi, M. Memmi et al., “Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model,” Circulation Research, vol. 99, no. 3, pp. 292–298, 2006.
[69]
C. B. Jung, A. Moretti, M. Mederos y Schnitzler et al., “Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia,” EMBO Molecular Medicine, vol. 4, no. 3, pp. 180–191, 2012.
[70]
H. Watanabe, C. van der Werf, F. Roses-Noguer et al., “Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia,” Heart Rhythm, vol. 10, no. 4, pp. 542–547, 2013.
[71]
C. M. Friesen, J. B. Brodsky, and M. F. Dillingham, “Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report,” Canadian Anaesthetists Society Journal, vol. 26, no. 4, pp. 319–321, 1979.
[72]
L. Crotti, G. Celano, F. Dagradi, and P. J. Schwartz, “Congenital long QT syndrome,” Orphanet Journal of Rare Diseases, vol. 3, no. 1, article 18, 2008.
[73]
M. Taglialatela, A. Pannaccione, P. Castaldo, G. Giorgio, and L. Annunziato, “Inhibition of HERG1 K+ channels by the novel second-generation antihistamine mizolastine,” British Journal of Pharmacology, vol. 131, no. 6, pp. 1081–1088, 2000.
[74]
D. Nuyens, M. Stengl, S. Dugarmaa et al., “Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome,” Nature Medicine, vol. 7, no. 9, pp. 1021–1027, 2001.
[75]
A. Moretti, M. Bellin, A. Welling et al., “Patient-specific induced pluripotent stem-cell models for long-QT syndrome,” The New England Journal of Medicine, vol. 363, no. 15, pp. 1397–1409, 2010.
[76]
I. Itzhaki, L. Maizels, I. Huber et al., “Modelling the long QT syndrome with induced pluripotent stem cells,” Nature, vol. 471, no. 7337, pp. 225–230, 2011.
[77]
E. Matsa, D. Rajamohan, E. Dick et al., “Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation,” European Heart Journal, vol. 32, no. 8, pp. 952–962, 2011.
[78]
S. P. Pa？ca, T. Portmann, I. Voineagu et al., “Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome,” Nature Medicine, vol. 17, no. 12, pp. 1657–1662, 2011.
[79]
R. Frank, G. Fontaine, J. Vedel et al., “Electrocardiologie de quatre cas de dysplasie ventriculaire droite arythmogene,” Archives des Maladies du Coeur et des Vaisseaux, vol. 71, pp. 963–972, 1978.
[80]
G. Thiene, D. Corrado, and C. Basso, “Arrhythmogenic right ventricular cardiomyopathy/dysplasia,” Orphanet Journal of Rare Diseases, vol. 2, no. 1, article 45, 2007.
[81]
M. A. Schwarz, K. Owaribe, J. Kartenbeck, and W. W. Franke, “Desmosomes and hemidesmosomes: constitutive molecular components,” Annual Review of Cell Biology, vol. 6, pp. 461–491, 1990.
[82]
A. Rampazzo, “Genetic bases of arrhythmogenic right ventricular cardiomyopathy,” Heart International, vol. 2, pp. 17–26, 2006.
[83]
C. Wrzodek, A. Dr？ger, and A. Zell, “Graphical representation of “Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (Ornithorhynchus anatinus (platypus))’,” Bioinformatics, vol. 27, pp. 2314–2315, 2011.
[84]
Z. Yang, N. E. Bowles, S. E. Scherer et al., “Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy,” Circulation Research, vol. 99, no. 6, pp. 646–655, 2006.
[85]
R. Lombardi, M. da Graca Cabreira-Hansen, A. Bell, R. R. Fromm, J. T. Willerson, and A. J. Marian, “Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy,” Circulation Research, vol. 109, no. 12, pp. 1342–1353, 2011.
[86]
D. Ma, H. Wei, J. Lu et al., “Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy,” European Heart Journal, vol. 34, no. 15, pp. 1122–1133, 2013.
[87]
C. Kim, J. Wong, J. Wen et al., “Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs,” Nature, vol. 494, no. 7435, pp. 105–110, 2013.
[88]
O. Caspi, I. Huber, A. Gepstein et al., “Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells,” Circulation: Cardiovascular Genetics, vol. 6, no. 6, pp. 557–568, 2013.
[89]
V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. 188–197, 2012.
